Serum peptide reactivities may distinguish neuromyelitis optica subgroups and multiple sclerosis
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received October 14, 2015
- Accepted in final form December 15, 2015
- First Published February 2, 2016.
Author Disclosures
- Imke Metz, MD*,
- Tim Beißbarth, PhD*,
- David Ellenberger,
- Florence Pache, MD,
- Lidia Stork,
- Marius Ringelstein, MD,
- Orhan Aktas, MD,
- Sven Jarius, MD,
- Brigitte Wildemann, MD,
- Hassan Dihazi, PhD,
- Tim Friede, PhD,
- Wolfgang Brück, MD,
- Klemens Ruprecht, MD‡ and
- Friedemann Paul, MD‡
- Imke Metz, MD*,
NONE
NONE
1)commercial: speaker honoraria, travel grants from BiogenIdec, Bayer Healthcare, TEVA, Serono, Novartis
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
research grant from BiogenIdec.
grants from German Ministry for Education and Research (BMBF, ??German Competence Network Multiple Sclerosis?? (KKNMS), Pattern MS/NMO);
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Tim Beißbarth, PhD*,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- David Ellenberger,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Florence Pache, MD,
NONE
NONE
(1) Commercial: Travel grant from Genzyme, a Sanofi Company (2) Commercial: Travel grant from Bayer (3) Commercial: Travel grant from Biogene Idec (4) Non-profit: Travel grant from ECTRIMS ( European Committee for Treatment and Research in Multiple Sclerosis)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) governmental grant to Friedemann Paul- used for 50 % of my employment: KKNMS- Bundesministerium f?r Bildung und Forschung-governmental support- Ministry in Germany (“) commercial grant to Friedemann Paul- used for a short time part employment to me: Novartis-no significant conflict of interest
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Lidia Stork,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Marius Ringelstein, MD,
NONE
NONE
1. Novartis, funding for speaking at a confeence. 2. Bayer Schering, funding for travel to a conference. 3. Biogen Idec, funding for travel to a conference. 4. Genzyme, funding for travel to a conference.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Orhan Aktas, MD,
(1) Medimmune Scientific Advisory Board
NONE
(1) Bayer, travel and speaker honoraria (2) Novartis, travel and speaker honoraria (3) Biogen, travel and speaker honoraria (4) Merck, travel and speaker honoraria (5) Serono, travel and speaker honoraria (6) Teva, travel and speaker honoraria (7) Genzyme, travel and speaker honoraria
(1) PLoS ONE, Academic Editor, since 2012
NONE
NONE
NONE
(1) Novartis
NONE
NONE
NONE
(1) Novartis (2) Bayer (3) Biogen
(1) German Research Foundation (DFG), SFB974 (2) German Research Foundation (DFG), GRK1033 (3) German Ministry of Science (BMBF), EU-FP7
(1) German Research Foundation (DFG)
(1) Heinrich and Erna Schaufler-Foundation (2) Walter and Ilse Rose-Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Sven Jarius, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Brigitte Wildemann, MD,
Brigitte Wildemann served on scientific advisory boards for Novartis
NONE
Brigitte Wildemann has received funding for travel and speaker honoraria from Bayer Healthcare, Biogen, Merck Serono, Genzyme,a Sanofi Company, Novartis Pharmaceuticals, and Teva Pharma
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Brigitte Wildemann has has received research support from Biogen Idec, Biotest, Merck Serono, Novartis Pharmaceuticals, Teva Pharma, the Dietmar-Hopp-Foundation, and the German Ministry of Education and Research (BMBF)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Hassan Dihazi, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Tim Friede, PhD,
(1) Biogen (2) Novartis (3) Bayer (4) Janssen (5) Gr?nenthal
NONE
NONE
(1) Biometrical Journal, Editor, 2009-2011 (2) Biometrical Journal, Associate Editor, since 2012 (3) BMC Medical Research Methodology, since 2011 (4) PLoS ONE, Academic Editor, 2013-2015 (5) PLoS ONE, Section Editor, since 2015
NONE
NONE
NONE
(1) Novartis Pharma AG, consultant, since 2007 (2) Pharmalog Institut f?r Klinische Forschung GmbH, consultant, since 2006 (3) Biogen Idec, consultant, 2012-2013 (4) Bayer, consultant, since 2015
NONE
NONE
NONE
NONE
(1) Deutsche Forschungsgemeinschaft, Principal investigator, FR-3070/1-1, 2012-2016 (2) Bundesministerium f?r Bildung und Forschung, Principal investigator, 13 6406 0, 2011-2015 (3) Executive Agency for Health and Consumers, Principal investigator, 2010 12 13, 2011-2014 (4) Bundesministerium f?r Bildung und Forschung, Principal investigator, 13 6442 0, 2013-2016 (5) EU's 7th Framework Programme for research, technological development and demonstration, Principal investigator, FP HEALTH 2013 ? 602144, 2014-2017
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Wolfgang Brück, MD,
I serve on the advisory board of Genzyme, Novartis, Biogen Idec Germany and Teva Pharma.
NONE
I received honoraria for oral presentations from Teva, Sanofi, Genzyme, Novartis, Merck-Serono, Biogen and Bayer in the last 2 years.
I am editorial board member of Acta neuropathologica, Therapeutic Advances in Neurological disorders, Multiple Sclerosis International and Neuropathology and Applied Neurobiology
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
German Research foundation (DFG SFB TR43): The brain as atarget of inflammatory processes, 2008-2015German ministry for science and education: Competencenetwork multiple sclerosis, 2010-2015
NONE
Tschira Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Klemens Ruprecht, MD‡ and
(1)sanofi-aventis/Genzyme (2)Novartis (3)Roche
NONE
(1)Bayer Healthcare, travel and speaker honoraria (2)Biogen Idec, travel and speaker honoraria (3)Merck Serono, travel and speaker honoraria (4)sanofi-aventis/Genzyme, travel and speaker honoraria (5)Teva Pharmaceuticals, travel and speaker honoraria (6)Novartis, travel and speaker honoraria (7)Guthy Jackson Charitable Foundation, travel honoraria
(1) PLOS ONE, Academic Editor, since 2013
NONE
(1) Neurologie in Frage und Antwort, Elsevier, 2000-2015
NONE
NONE
NONE
NONE
NONE
(1) Novartis
(1)German Ministry of Education and Research (BMBF/KKNMS, Competence Network Multiple Sclerosis)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Friedemann Paul, MD‡
Novartis OCTIMS study steering committee MedImmune steering committee
NONE
speaker honoraria and travel grants from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis / Genzyme, and Merck Serono
Academic Editor, PLoS ONE Associate Editor, Neurology Neuroimmunology and Neuroinflammation
NONE
NONE
NONE
consultancies for SanofiGenzyme, BiogenIdec, MedImmune
NONE
NONE
NONE
Research support from from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis / Genzyme, and Merck Serono
German Research Council (DFG Exc 257), Werth Stiftung of the City of Cologne, German Ministry of Education and Research (BMBF Competence Network Multiple Sclerosis), Arthur Arnstein Stiftung Berlin, EU FP7 Framework Program (combims.eu)
NONE
Arthur Arnstein Foundation Berlin, Guthy Jackson Charitable Foundation, National Multiple Sclerosis Society of the USA
NONE
NONE
NONE
NONE
NONE
NONE
- From the Departments of Neuropathology (I.M., L.S., W.B.), Medical Statistics (T.B., D.E., T.F.), and Nephrology and Rheumatology, Internal Medicine (H.D.), University Medical Center Göttingen; Department of Neurology (F. Pache, K.R., F. Paul) and Clinical and Experimental Multiple Sclerosis Research Center (F. Pache, K.R., F. Paul), Charité–Universitätsmedizin Berlin; NeuroCure Clinical Research Center and Experimental and Clinical Research Center (F. Pache, F. Paul), Max Delbrueck Center for Molecular Medicine; Department of Neurology (M.R., O.A.), Medical Faculty, Heinrich-Heine-University Düsseldorf; and Molecular Neuroimmunology Group, Department of Neurology (S.J., B.W.), University of Heidelberg, Germany.
- Correspondence to Dr. Brück: wbrueck{at}med.uni-goettingen.de
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Nicole Sur and Dr. Mausaminben Hathidara
► Watch
Alert Me
Recommended articles
-
Article
Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disordersDouglas Kazutoshi Sato, Dagoberto Callegaro, Marco Aurelio Lana-Peixoto et al.Neurology, January 10, 2014 -
Article
Fulminant demyelinating encephalomyelitisInsights from antibody studies and neuropathologyFranziska Di Pauli, Romana Höftberger, Markus Reindl et al.Neurology - Neuroimmunology Neuroinflammation, November 04, 2015 -
Article
Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritisSudarshini Ramanathan, Stephen W. Reddel, Andrew Henderson et al.Neurology - Neuroimmunology Neuroinflammation, October 29, 2014 -
Article
Protein array–based profiling of CSF identifies RBPJ as an autoantigen in multiple sclerosisLuis Querol, Pamela L. Clark, Mary A. Bailey et al.Neurology, August 06, 2013